Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 11/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 8/20 | 0.45 |
| ▸ | PIK3CB | P42338 | 7/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 7/20 | 0.45 |
| ▸ | MTOR | P42345 | 2/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PIK3R1 | P27986 | 4/20 | 0.39 |
| ▸ | BACE1 | P56817 | 3/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.35 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2711268 | 0.77 | PIK3CA (0.46) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL2712621 | 0.76 | PIK3CA (0.57) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL20242081 | 0.76 | PIK3CA (0.48) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL22820581 | 0.76 | HTT (0.41) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL23092185 | 0.75 | BACE1 (0.42) | PIK3CAPIK3CDPIK3CBPIK3CGBACE1 | |
| SCHEMBL18248008 | 0.74 | PIK3CD (0.43) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL29551535 | 0.74 | PIK3CD (0.43) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL2712585 | 0.73 | CYP11B2 (0.46) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL10008830 | 0.73 | PIK3CA (0.42) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL24156076 | 0.70 | PIK3CD (0.40) | PIK3CAPIK3CDPIK3CBPIK3CGCYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250361237-A1 | 1,4-DIHYDROBENZO[D]PYRAZOLO[3,4-F][1,3]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS LRRK2, NUAK1 AND/OR TYK2 KINASE MODULATORS FOR THE TREATMENT OF E.G. AUTOIMMUNE DISEASE | ORIGENIS GMBH (DE) | 2025-11-27 | — | — | US | disclosed |
| US-12384788-B2 | 1,4-dihydrobenzo[d]pyrazolo[3,4-f][1,3]diazepine derivatives and related compounds as LRRK2, NUAK1 and/or TYK2 kinase modulators for the treatment of e.g. autoimmune disease | ORIGENIS GMBH (DE) | 2025-08-12 | — | — | US | disclosed |
| US-20220380374-A1 | 1,4-DIHYDROBENZO[D]PYRAZOLO[3,4-F][1,3]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS LRRK2, NUAK1 AND/OR TYK2 KINASE MODULATORS FOR THE TREATMENT OF E.G. AUTOIMMUNE DISEASE | ORIGENIS GMBH (DE) | 2022-12-01 | — | — | US | disclosed |
| US-20220380373-A1 | 1,4-DIHYDROBENZO[D]PYRAZOLO[3,4-F][1,3]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS LRRK2, NUAK1 AND/OR TYK2 KINASE MODULATORS FOR THE TREATMENT OF E.G. AUTOIMMUNE DISEASE | ORIGENIS GMBH (DE) | 2022-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12384788-B2 | 1,4-dihydrobenzo[d]pyrazolo[3,4-f][1,3]diazepine derivatives and related compounds as LRRK2, NUAK1 and/or TYK2 kinase modulators for the treatment of e.g. autoimmune disease | NUAK1, TYK2, MARK1 | PIK3CA 972/4885PIK3CD 1526/4885PIK3CB 1344/4885 |
| US-20220380374-A1 | 1,4-DIHYDROBENZO[D]PYRAZOLO[3,4-F][1,3]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS LRRK2, NUAK1 AND/OR TYK2 KINASE MODULATORS FOR THE TREATMENT OF E.G. AUTOIMMUNE DISEASE | NUAK1, TYK2, MARK1 | PIK3CA 974/4885PIK3CD 1537/4885PIK3CB 1348/4885 |
| US-20220380373-A1 | 1,4-DIHYDROBENZO[D]PYRAZOLO[3,4-F][1,3]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS LRRK2, NUAK1 AND/OR TYK2 KINASE MODULATORS FOR THE TREATMENT OF E.G. AUTOIMMUNE DISEASE | NUAK1, TYK2, MARK1 | PIK3CA 972/4885PIK3CD 1526/4885PIK3CB 1344/4885 |
| US-20250361237-A1 | 1,4-DIHYDROBENZO[D]PYRAZOLO[3,4-F][1,3]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS LRRK2, NUAK1 AND/OR TYK2 KINASE MODULATORS FOR THE TREATMENT OF E.G. AUTOIMMUNE DISEASE | NUAK1, TYK2, MARK1 | PIK3CA 972/4885PIK3CD 1526/4885PIK3CB 1344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.